Log in

Seneca Biopharma Stock Forecast, Price & News

-0.01 (-1.64 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $0.60
50-Day Range
MA: $0.61
52-Week Range
Now: $0.60
Volume255,836 shs
Average Volume1.56 million shs
Market Capitalization$10.38 million
P/E RatioN/A
Dividend YieldN/A
Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidates include NSI-189, a chemical entity, which has been completed Phase II clinical trials for the treatment of major depressive disorder; and NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.59 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:SNCA



Sales & Book Value

Annual Sales$10,000.00
Book Value$1.33 per share


Net Income$-8,350,000.00
Net Margins-221.07%


Market Cap$10.38 million
Next Earnings Date3/26/2021 (Estimated)
OptionableNot Optionable
-0.01 (-1.64 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNCA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNCA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Seneca Biopharma (NASDAQ:SNCA) Frequently Asked Questions

How has Seneca Biopharma's stock been impacted by Coronavirus?

Seneca Biopharma's stock was trading at $0.7209 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SNCA stock has decreased by 16.8% and is now trading at $0.60.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than Seneca Biopharma?

Wall Street analysts have given Seneca Biopharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Seneca Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Seneca Biopharma's next earnings date?

Seneca Biopharma is scheduled to release its next quarterly earnings announcement on Friday, March 26th 2021.
View our earnings forecast for Seneca Biopharma

How were Seneca Biopharma's earnings last quarter?

Seneca Biopharma, Inc. (NASDAQ:SNCA) released its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.13) EPS for the quarter. Seneca Biopharma had a negative return on equity of 138.92% and a negative net margin of 221.07%.
View Seneca Biopharma's earnings history

Are investors shorting Seneca Biopharma?

Seneca Biopharma saw a decrease in short interest in October. As of October 30th, there was short interest totaling 68,800 shares, a decrease of 29.5% from the October 15th total of 97,600 shares. Based on an average daily trading volume, of 330,500 shares, the short-interest ratio is presently 0.2 days. Approximately 0.4% of the shares of the company are sold short.
View Seneca Biopharma's Short Interest

Who are some of Seneca Biopharma's key competitors?

What other stocks do shareholders of Seneca Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seneca Biopharma investors own include OpGen (OPGN), Sorrento Therapeutics (SRNE), AIM ImmunoTech (AIM), DURECT (DRRX), Nabriva Therapeutics (NBRV), OPKO Health (OPK), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Fulcrum Therapeutics (FULC) and iBio (IBIO).

Who are Seneca Biopharma's key executives?

Seneca Biopharma's management team includes the following people:
  • Dr. Kenneth C. Carter, Exec. Chairman & CEO (Age 60, Pay $415k)
  • Dr. Matthew W. Kalnik Ph.D., Pres & COO (Age 57)
  • Dr. Karl Y. Johe, Co-Founder (Age 60)
  • Mr. Dane R. Saglio, Chief Financial Officer (Age 62)
  • Dr. Thomas G. Hazel, Sr. VP of R&D
  • Dr. David P. Recker FACR, M.D., FACP, Chief Medical Officer (Age 62)

What is Seneca Biopharma's stock symbol?

Seneca Biopharma trades on the NASDAQ under the ticker symbol "SNCA."

How do I buy shares of Seneca Biopharma?

Shares of SNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Seneca Biopharma's stock price today?

One share of SNCA stock can currently be purchased for approximately $0.60.

How big of a company is Seneca Biopharma?

Seneca Biopharma has a market capitalization of $10.38 million and generates $10,000.00 in revenue each year. Seneca Biopharma employs 7 workers across the globe.

What is Seneca Biopharma's official website?

The official website for Seneca Biopharma is www.senecabio.com.

How can I contact Seneca Biopharma?

Seneca Biopharma's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.